• Gastrin I (human): Unraveling Receptor Biology and Translati

  2026-06-16

  Explore the pivotal role of Gastrin I (human) in decoding gastric acid secretion pathways with unprecedented receptor-level detail. This article uniquely bridges advanced peptide biochemistry with hiPSC-derived intestinal organoid models, delivering actionable insight for gastrointestinal physiology studies.

• EZ Cap™ Human PTEN mRNA (ψUTP): Redefining mRNA Stability an

  2026-06-16

  Explore how EZ Cap™ Human PTEN mRNA (ψUTP) advances in vitro transcribed mRNA research through enhanced stability and immune evasion. This article uniquely connects molecular engineering with translational oncology, highlighting practical assay implications and differentiating itself from existing PTEN mRNA content.

• Oteseconazole (VT-1161): Reliable Antifungal Data for Candid

  2026-06-15

  This evidence-driven article addresses key laboratory challenges in antifungal testing, focusing on Oteseconazole (VT-1161), SKU BA1665. By integrating real-world scenarios, data-backed protocols, and vendor reliability analysis, it empowers researchers and technicians to optimize Candida assays and confidently select Oteseconazole (VT-1161) for robust, reproducible results.

• Strategic Acceleration of MCL1-Targeted Therapeutics in Onco

  2026-06-15

  This thought-leadership article explores the mechanistic and translational significance of targeting MCL1 in overcoming endocrine resistance in breast cancer, leveraging the L1023 Anti-Cancer Compound Library for high-throughput discovery. By integrating recent findings on capsazepine's novel mechanism and mapping strategic workflows for translational research, it offers actionable guidance and a forward-looking vision for oncology drug discovery.

• AZD8055: Technical Guidance for mTOR Pathway Inhibition

  2026-06-14

  AZD8055 is a potent, selective mTOR inhibitor designed for preclinical research dissecting mTORC1 and mTORC2 signaling in cancer and metabolic models. It is not recommended for studies aiming to demonstrate clinical efficacy endpoints, but is highly effective for mechanistic studies requiring dual complex inhibition. This article details actionable workflow guidance and technical boundaries for AZD8055 use.

• AO/PI Double Staining Kit: Precision Cell Viability & Apopto

  2026-06-13

  The AO/PI Double Staining Kit enables rapid, quantitative differentiation of viable, apoptotic, and necrotic cells in complex experimental settings. Its dual-fluorescence design is uniquely suited for high-content organoid models and translational oncology workflows, streamlining both routine and advanced cell fate analysis.

• NF 449: Purinergic Receptor Antagonist Elevates Platelet Res

  2026-06-12

  NF 449, a highly selective purinergic receptor antagonist, streamlines platelet activation studies with unmatched potency at the P2X1 ion channel. Its precision enables advanced antithrombotic agent research, robust workflow reproducibility, and actionable troubleshooting for demanding platelet aggregation assays.

• Aquaporin-1 as a Safe Genetic MRI Reporter Across Cell Types

  2026-06-12

  The referenced study demonstrates that engineering water exchange via aquaporin-1 (Aqp1) enables robust, metal-free MRI contrast in diverse mammalian cells without compromising cell physiology. These findings address safety concerns and pave the way for broader applications of Aqp1 as a noninvasive genetic reporter in molecular and synthetic biology.

• CRISPRi Targeting Fabp4: Adipocyte-Specific Gene Silencing i

  2026-06-11

  This study demonstrates a targeted nonviral CRISPR interference system against Fabp4 in white adipocytes, leading to significant reductions in obesity, inflammation, hepatic steatosis, and insulin resistance in mouse models. The findings highlight a technically robust, tissue-specific gene modulation strategy with potential translational value for metabolic and liver disease research.

• Distinct Pharmacokinetics and Clinical Potential of Fosinopr

  2026-06-11

  The reference study delineates the unique pharmacokinetic profile and clinical potential of fosinopril sodium, a third-generation phosphinic acid ACE inhibitor. Its dual renal-hepatic elimination and robust blood pressure reduction make it a particularly valuable option in hypertension research and patient cohorts with renal impairment.

• PLAC1 as a Prognostic Biomarker and Target in ccRCC: Evidenc

  2026-06-10

  The reference study identifies PLAC1 as a prognostic biomarker and actionable molecular target in clear cell renal cell carcinoma (ccRCC), using a combination of transcriptomic analysis, in vitro validation, and high-throughput virtual screening. This work highlights both the mechanistic relevance of PLAC1 in tumor progression and the feasibility of targeting it with small-molecule inhibitors, offering new directions for precision oncology in renal cancer.

• A1 vs. AMD3100: Advancing CXCR4 Inhibition in Colorectal Can

  2026-06-10

  Khorramdelazad et al. introduce A1, a novel fluorinated CXCR4 inhibitor, demonstrating superior binding affinity and anti-tumor effects compared to AMD3100 in colorectal cancer models. Their findings sharpen the understanding of CXCL12/CXCR4 axis targeting and provide a foundation for next-generation cancer metastasis inhibition strategies.

• Capsazepine Targets MCL1 to Reverse Tamoxifen Resistance in

  2026-06-09

  This study identifies capsazepine as a direct MCL1 inhibitor capable of overcoming tamoxifen resistance in estrogen receptor-positive breast cancer. The work combines virtual screening, molecular docking, and functional validation to demonstrate capsazepine's efficacy and lays the foundation for new combinatorial therapeutic approaches.

• hiPSC-Derived Intestinal Organoids for Pharmacokinetic Studi

  2026-06-09

  This study establishes a streamlined protocol for generating intestinal organoids from human induced pluripotent stem cells (hiPSCs), enabling more physiologically relevant pharmacokinetic studies than traditional models. The organoids demonstrate sustained proliferation, differentiation, and key metabolic activities, offering a promising human-relevant platform for drug absorption and metabolism research.

• Phenacetin in Advanced Organoid PK: Solubility, QC, and Assa

  2026-06-08

  Explore the role of Phenacetin (N-(4-ethoxyphenyl)acetamide) in pharmacokinetic studies, with a focus on solubility, quality control, and cutting-edge organoid assay design. This article uniquely synthesizes product-specific data and recent organoid model advances to optimize your scientific research use.

14773 records 1/985 page Next 12345 下5页 Last page